RxDoctor Payments Data

Alexandru Topliceanu, MD

Cardiovascular Disease · Oklahoma City, OKNPI 1366728768

Payments from drug & device makers

$415in general payments, 2019–2025

Across 25 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$130
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$118
  • Kestra Medical Technology Services, Inc.$59
  • Pfizer$21
  • Novartis$21
  • E.r. Squibb & Sons, L.L.C.$18
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$41099%
  • Education$51%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$415 in reported general payments places this provider in the 15th percentile of 164 cardiovascular disease providers in Oklahoma.

See all cardiovascular disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$200,934
Medicare patients
2,458
Services billed
4,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban475$434,139
EntrestoSacubitril/Valsartan179$175,963
JardianceEmpagliflozin103$96,725
XareltoRivaroxaban67$77,061
Repatha SureclickEvolocumab40$25,197
MultaqDronedarone Hcl14$18,543
BrilintaTicagrelor11$12,883
Atorvastatin Calcium496$6,677
Metoprolol Succinate309$4,003
Ezetimibe123$3,364
Amiodarone Hcl87$3,011
Rosuvastatin Calcium106$2,180
Losartan Potassium138$2,165
Valsartan30$1,869
Lisinopril164$1,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$434,139475 claims
NovartisEntresto$21$175,963179 claims
Johnson & JohnsonXarelto$130$77,06167 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 164 cardiovascular disease providers in Oklahoma.

Other cardiovascular disease in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →